<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01721590</url>
  </required_header>
  <id_info>
    <org_study_id>SYNH-20120929</org_study_id>
    <nct_id>NCT01721590</nct_id>
  </id_info>
  <brief_title>Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease</brief_title>
  <acronym>Talent</acronym>
  <official_title>Study of Tongxinluo to Improve High on Clopidogrel Platelet Reactivity in Patients With Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han Yaling</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Northern Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tongxinluo is a kind of Chinese patent drug,which could promote blood circulation.Recent
      reports suggested that tongxinluo's effectiveness in reducing the thrombin activity.In this
      prospective randomized study,all patients in control group will receive blank placebo ,all
      patients in test group will receive tongxinluo.All patients will be followed up for one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint is Platelet Reaction Unit( by VerifyNow) at 30 days.The secondary
      endpoints include inflammation marker (hsCRP、CD62P-CD41),TT,FIB and PT at 30 days,and
      MI、Ischemic Stroke, target vessel revascularization and all-cause mortality 、bleeding events
      at 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reaction unit(PRU) measured by verifyNow</measure>
    <time_frame>1 month</time_frame>
    <description>to measure the rate of HPR(PRU ≤ 235)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation Marker (hsCRP、CD62P-CD41)</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma fibrinogen concentration</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin time</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin time</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiovascular events</measure>
    <time_frame>1 year</time_frame>
    <description>Including MI,Stroke,target vessel revascularization,and all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding event</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction and withdrawal rate</measure>
    <time_frame>1 month ，1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina recurrence</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Traditional Chinese medicine angina symptoms scores</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-stent thrombosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo，3 capsules/time，3times/day for 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tongxinluo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tongxinluo 3 capsules/time 3times/day for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tongxinluo</intervention_name>
    <description>Tongxinluo,3 capsules/time 3times/day for 1 year</description>
    <arm_group_label>Tongxinluo</arm_group_label>
    <other_name>Tongxinluo capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>3 capsules/time，3times/day for 1 year</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>placebo capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - (1)ACS (including unstable angina pectoris, non-ST-segment elevation myocardial
        infarction and ST-elevation myocardial infarction) （2）Accept at least one coronary stent.
        （3）The age between18 and 75 . （4）High on-treatment platelet reactivity defined as an
        ADP-induced platelet aggregation (by VerifyNow，PRU≥236）at 24 hr after clopidogrel loading
        (300 ~ 600mg)or 24 hours after PCI.

        （5）Informed Consent

        Exclusion Criteria:

          -  （1）Tongxinluo contraindication . （2）Receiving GP IIb / IIIa receptor antagonist
             treatment （3）Who complicate the known bleeding tendency and blood system diseases.
             （4）NYHA grade III ~ IV （5）Aspirin or clopidogrel allergies （6）Severe liver or kidney
             dysfunction （7）Pregnancy （8）Cann't accept 30 days supervision and blood proofer.
             （9）Other serious illness, life expectancy less than 6 months. （10) Planned surgery
             recently （11) PCI again within 30 days. (12) Mental diseases interfering understanding
             the informed consent form （13）Accept other drugs or participate in other clinical
             research at the same time .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaling Han, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shenyang Northern Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ShenZhou Hopital Of ShenYang Medical College</name>
      <address>
        <city>ShengYang</city>
        <state>Liaoning</state>
        <zip>110032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 463th Hospital Of PLA</name>
      <address>
        <city>ShenYang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2012</study_first_submitted>
  <study_first_submitted_qc>November 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2012</study_first_posted>
  <last_update_submitted>December 21, 2015</last_update_submitted>
  <last_update_submitted_qc>December 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shenyang Northern Hospital</investigator_affiliation>
    <investigator_full_name>Han Yaling</investigator_full_name>
    <investigator_title>vice president</investigator_title>
  </responsible_party>
  <keyword>high on-treatment platelet reactivity</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Tongxinluo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

